Edition:
United States

Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671.SS)

600671.SS on Shanghai Stock Exchange

19.16CNY
18 May 2018
Change (% chg)

¥-0.10 (-0.52%)
Prev Close
¥19.26
Open
¥19.37
Day's High
¥19.39
Day's Low
¥19.06
Volume
1,207,070
Avg. Vol
1,128,164
52-wk High
¥29.60
52-wk Low
¥16.11

Latest Key Developments (Source: Significant Developments)

Hangzhou TianMuShan Pharmaceutical Enterprise sees FY 2017 net profit up 568.88 pct
Friday, 27 Apr 2018 07:21am EDT 

April 27(Reuters) - Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd <600671.SS>:Sees FY 2017 net profit to increase by 568.88 percent, or to be 8.1 million yuan .Says FY 2016 net profit was 1.2 million yuan.  Full Article

Hangzhou Tianmushan Pharmaceutical Enterprise receives GMP certificate
Tuesday, 13 Feb 2018 03:51am EST 

Feb 13 (Reuters) - Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd <600671.SS> ::* Says it received goods manufacture practice (GMP) certificate from Zhejiang Food and Drug Administration .* Certificate issued eyedrops manufactured by the company and valid period is until Feb. 8, 2023.  Full Article

Hangzhou Tianmushan Pharmaceutical Enterprise sees FY 2017 net profit up 1,872 pct to 2,364 pct
Thursday, 1 Feb 2018 04:51am EST 

Feb 1(Reuters) - Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd <600671.SS> : :Sees FY 2017 net profit to increase by 1,872 percent to 2,364 percent, or to be 24 million yuan to 30 million yuan.Says FY 2016 net profit was 1.2 million yuan.The reasons for the forecast are production recovery and assets disposal .  Full Article

Hangzhou TianMuShan Pharmaceutical Enterprise unit obtains high-tech enterprise recognition again
Thursday, 11 Jan 2018 03:31am EST 

Jan 11 (Reuters) - Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd <600671.SS>:Says Huangshan-based pharmaceutical unit was recognized as high-tech enterprise again and could enjoy a tax preference of 15 percent, from 2017 to 2019.  Full Article

Hangzhou Tianmushan Pharmaceutical Scraps Asset Restructuring Plan
Tuesday, 2 Jan 2018 05:22am EST 

Jan 2 (Reuters) - Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd <600671.SS>::SAYS IT SCRAPS ASSET RESTRUCTURING PLAN, SHARE TRADE TO RESUME ON JAN 3.  Full Article

Hangzhou Tianmushan Pharma Halts Acquisition Plan As Related Parties Fail To Reach Agreement
Friday, 29 Dec 2017 06:54am EST 

Dec 29 (Reuters) - Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd <600671.SS>::SAYS IT HALTS ASSETS ACQUISITION PLAN AS RELATED PARTIES FAIL TO REACH AGREEMENT.  Full Article

Hangzhou TianMuShan Pharmaceutical Enterprise unit wins land auction for 43.1 mln yuan
Friday, 22 Dec 2017 12:32am EST 

Dec 22(Reuters) - Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd <600671.SS>:Says its unit won a land auction for 43.1 million yuan .  Full Article

Hangzhou TianMuShan Pharmaceutical Enterprise to set up pension and health care JV in Yinchuan
Wednesday, 18 Oct 2017 12:11am EDT 

Oct 18(Reuters) - Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd <600671.SS>:Says it plans to invest 28.2 million yuan to set up a pension and health care JV in Yinchuan with two limited partnerships, with registered capital of 47 million yuan .  Full Article

Hangzhou Tianmushan Pharmaceutical Enterprise unit receives GMP certificate
Friday, 30 Jun 2017 03:13am EDT 

June 30 (Reuters) - Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd <600671.SS> ::* Says its unit received goods manufacture practice (GMP) certificate from Anhui Food and Drug Administration .* Certificate issued tablets, granules, pills manufactured by the unit and the valid period is until June 27, 2022.  Full Article

Hangzhou Tianmushan Pharma to acquire Anhui firm for 360 mln yuan via cash, share issue
Monday, 26 Jun 2017 08:40am EDT 

June 26 (Reuters) - Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd <600671.SS>:Says to acquire Anhui pharmaceutical firm for an estimated 360 million yuan ($52.65 million) via cash, share issue.Says it plans to raise up to 180 million yuan in share private placement to help fund acquisition.  Full Article